Answers are grounded in this paper and cite their sources.
Depressive symptoms are highly prevalent among patients with hepatocellular carcinoma (HCC), yet whether they influence the efficacy of immunotherapy and the underlying mechanisms remain unclear. Integrated analyses of a clinical cohort and murine models demonstrate that chronic stress‐induced depressive‐like states markedly attenuate the antitumor efficacy of anti‐programmed cell death protein 1 (PD‐1) antibodies in HCC, accompanied by enhanced Tcell exhaustion. Mechanistically, chronic stress upregulates hepatic sulfotransferase 1A1 (SULT1A1) expression, thereby promoting the production of the tryptophan metabolite indoxyl sulfate (IS). IS does not directly act on CD8 + T cells but activates the transcription factor aryl hydrocarbon receptor (AHR) in HCC cells, upregulating the E3 ubiquitin ligase ring finger protein 115 (RNF115). RNF115 mediates lysine 27 (K27)‐linked ubiquitination of histone deacetylase 8 (HDAC8) to inhibit its autophagic degradation. Stabilized HDAC8 enhances secretion of the immunosuppressive factor angiopoietin‐like protein 4 (ANGPTL4), thereby contributing to CD8 + Tcell exhaustion and reducing sensitivity to PD‐1 inhibitors. Depletion or inhibition of HDAC8 significantly restores the antitumor efficacy of PD‐1 therapy under chronic stress. Collectively, these findings support a chronic stress‐SULT1A1‐IS‐AHR‐RNF115‐HDAC8 axis that drives immunotherapy resistance in HCC, suggesting a mechanistic link between emotional disturbance and tumor immune microenvironment remodeling.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: